Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2020

Open Access 01-04-2020 | Breast Cancer | Research Article

Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis

Authors: N. Wu, F. Fu, L. Chen, Y. Lin, P. Yang, C. Wang

Published in: Clinical and Translational Oncology | Issue 4/2020

Login to get access

Abstract

Background

The prognostic and clinical significance of single hormone receptor expression in breast cancer has not been clearly established. The goal of this study was to conduct a meta-analysis to compare the clinical outcomes of patients with ER+PR− tumours and ER−PR+ tumours to those of patients with ER+PR+ tumours.

Methods

A systematic review of the literature was conducted to identify studies that compared the clinical outcome of patients with ER+PR− tumours or ER−PR+ tumours with those of patients with ER+PR+ tumours. A total of 18 studies met the inclusion criteria and included 217,485 women. Standard methods for meta-analysis were used, including fixed-effect models.

Results

Patients with ER+PR− tumours or ER−PR+ tumours had significantly worse DFS (HR 1.60, 95% CI 1.44–1.77 and HR 2.27, 95% CI 1.67–3.09), BCSS (HR 1.43, 95% CI 1.33–1.53 and HR 1.82, 95% CI 1.68–1.98) and OS (HR 1.38, 95% CI 1.28–1.47 and HR 1.48, 95% CI 1.17–1.89) than those of patients with ER+PR+ tumours. In subgroup analyses, patients who had ER+PR− tumours experienced a higher risk of recurrence than patients with ER+PR+ tumours in the HER2− (HR 1.57, 95% CI 1.32–1.87), LN − (HR 2.07, 95% CI 1.44–2.86) and endocrine therapy (HR 1.65, 95% CI 1.45–1.89) subgroup. Patients who had HER2− and ER−PR+ tumours had an increased risk of recurrence compared with patients who had HER2− and ER+PR+ tumours (HR 3.10, 95% CI 1.92–5.10).

Conclusions

Among patients with hormone receptor-positive breast cancer, patients with either ER+PR− tumours or ER−PR+ tumours have a higher risk of recurrence and a shorter survival time than those with ER+PR+ tumours. Patients with both types of breast cancer need additional or better treatments.
Appendix
Available only for authorised users
Literature
1.
Beatson GT. On the treatment of inoperable cases of carcinoma of the manna; suggestion for a new method of treatment with illustrative cases. Lancet (London, England). 1896;2:104–7.
2.
Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet (London, England). 1987;2:171–5.
3.
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet (London, England). 1998;351:1451–67.
4.
Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet (London, England). 1992;339:71–85.
5.
Pichon MF, Pallud C, Brunet M, Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Can Res. 1980;40:3357–60.
6.
Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, Lesperance ML. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:1769–70.
7.
Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014;110:565–72.PubMed
8.
Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19:931–42.
9.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMed
10.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedPubMedCentral
11.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMed
12.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed.). 2003;327:557–60.
13.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMed
14.
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.PubMed
15.
Stang A. Critical evaluation of the Newcastle–Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
16.
Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:4772–8.
17.
Ma RM, Chen CZ, Lin CQ, Zhan W, Guo GL. Lack of progesterone receptor expression predicts poor prognosis in patients with operable ER-positive invasive breast cancer. Chin J Oncol. 2016;38:687–92.
18.
Chen H, Mo L, Xu XF, Gu J. Analysis of prognosis-related factors for breast cancer with positive estrogen receptors. Chin Clin Oncol. 2015;20:333–7.
19.
Bal O, Yalcintas Arslan U, Durnali A, Uyetrk U, Demirci A, Tastekin D, Ekinci A, Esbah O, Turker I, Uysal Sonmez O, Oksuzoglu B. Progesterone receptor status in determining the prognosis of estrogen receptor positive/HER2 negative breast carcinoma patients. J BUON Off J Balkan Union Oncol. 2015;20:28–34.
20.
Yu KD, Jiang YZ, Hao S, Shao ZM. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. BMC Med. 2015;13:254.PubMedPubMedCentral
21.
Itoh M, Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, Taira N, Niikura N, Hayashi N, Ohtani S, Higaki K, Fujiwara T, Doihara H, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Res Treat. 2014;143:403–9.PubMed
22.
Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M. Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:661–8.
23.
Park S, Park BW, Kim TH, Jeon CW, Kang HS, Choi JE, Hwang KT, Kim IC. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype. Ann Surg Oncol. 2013;20:1505–13.PubMed
24.
Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ. Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015;15:138.PubMedPubMedCentral
25.
Ng CH, Pathy NB, Taib NA, Ho GF, Mun KS, Rhodes A, Looi LM, Yip CH. Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers? Asian Pac J Cancer Prev APJCP. 2014;15:7959–64.PubMed
26.
Li H, Zhao M, Tao P, Li H, Liu F, Li JY. Prognostic value of progesterone receptor status in Chinese breast cancer patients treated with tamoxifen. Int J Clin Exp Med. 2016;9:2175–83.
27.
Shen T, Brandwein-Gensler M, Hameed O, Siegal GP, Wei S. Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. Hum Pathol. 2015;46:1776–844.PubMed
28.
Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Esmailnasab N, Babaee E. Breast cancer survival analysis based on immunohistochemistry subtypes (ER/PR/HER2): a retrospective cohort study. Arch Iran Med. 2016;19:680–6.PubMed
29.
Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:4835–42.
30.
Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res BCR. 2007;9:R6.PubMed
31.
Keshgegian AA, Cnaan A. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome. Arch Pathol Lab Med. 1996;120:970–3.PubMed
32.
Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:1973–9.
33.
Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96:218–28.PubMed
34.
Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254–61.PubMed
35.
Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:7721–35.
36.
Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (London, England). 2011;378:771–84.
37.
Zhang Y, Su H, Rahimi M, Tochihara R, Tang C. EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer. 2009;125:2021–8.PubMedPubMedCentral
38.
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006;106:2576–82.PubMed
39.
Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science (New York, N.Y.). 1975;189:726–7.
40.
Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology. 1978;103:1742–51.PubMed
41.
Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10:331s–6s.
42.
Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:865s–70s.
43.
De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, Wildiers H, Paridaens R, Smeets A, Christiaens MR, Vergote I, Leunen K, Amant F, Neven P. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:335–6 (author reply 336-338).
44.
Ahmed SS, Thike AA, Zhang K, Lim JC, Tan PH. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group. J Clin Pathol. 2017;70:320–6.PubMed
45.
Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009;114:287–99.PubMed
46.
Kiani J, Khan A, Khawar H, Shuaib F, Pervez S. Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity? Pathol Oncol Res POR. 2006;12:223–7.PubMed
47.
Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment. J Cancer Res Clin Oncol. 2008;134:1347–54.PubMed
48.
Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, Beck AH. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res BCR. 2013;15:R68.PubMed
49.
Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6:195–7.PubMedPubMedCentral
Metadata
Title
Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis
Authors
N. Wu
F. Fu
L. Chen
Y. Lin
P. Yang
C. Wang
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 4/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02149-0

Other articles of this Issue 4/2020

Clinical and Translational Oncology 4/2020 Go to the issue

Research Article

The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients

Research Article

Stromal fibroblast-derived MFAP5 promotes the invasion and migration of breast cancer cells via Notch1/slug signaling

Research Article

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

Research Article

Evaluation of axillary lymph node metastasis burden by preoperative ultrasound in early-stage breast cancer with needle biopsy-proven metastasis

Research Article

Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients

Review Article

Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits